Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLand & ImprovementsLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVJF) Operating Leases (2018 - 2025)

Historic Operating Leases for Teva Pharmaceutical Industries (TEVJF) over the last 9 years, with Q4 2025 value amounting to $288.0 million.

  • Teva Pharmaceutical Industries' Operating Leases fell 270.27% to $288.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $288.0 million, marking a year-over-year decrease of 270.27%. This contributed to the annual value of $288.0 million for FY2025, which is 270.27% down from last year.
  • Teva Pharmaceutical Industries' Operating Leases amounted to $288.0 million in Q4 2025, which was down 270.27% from $283.0 million recorded in Q3 2025.
  • In the past 5 years, Teva Pharmaceutical Industries' Operating Leases ranged from a high of $525.0 million in Q4 2021 and a low of $281.0 million during Q2 2024
  • In the last 5 years, Teva Pharmaceutical Industries' Operating Leases had a median value of $341.5 million in 2023 and averaged $357.0 million.
  • As far as peak fluctuations go, Teva Pharmaceutical Industries' Operating Leases skyrocketed by 729.93% in 2021, and later tumbled by 2901.68% in 2024.
  • Over the past 5 years, Teva Pharmaceutical Industries' Operating Leases (Quarter) stood at $525.0 million in 2021, then decreased by 15.81% to $442.0 million in 2022, then fell by 5.66% to $417.0 million in 2023, then decreased by 29.02% to $296.0 million in 2024, then dropped by 2.7% to $288.0 million in 2025.
  • Its last three reported values are $288.0 million in Q4 2025, $283.0 million for Q3 2025, and $296.0 million during Q2 2025.